Taken together, the data from several murine models of non-diabetic hyperfiltration, hypervolemia and hypertension suggest that nephroprotection by the SGLT2 inhibitor empagliflozin requires a functional TGF mechanism to reduce chronic hyperfiltration and protect animals from glomerular damage and albuminuria. This evidence concerns the gene SLC5A2 and Hypertension.